|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | G01N 33/574 | |
| G01N 33/74 |
| (11) | Patento numeris | 2753933 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12766763.2 |
| Europos patento paraiškos padavimo data | 2012-09-07 | |
| (97) | Europos patento paraiškos paskelbimo data | 2014-07-16 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-08-09 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2012/054137 |
| Data | 2012-09-07 |
| (87) | Numeris | WO 2013/066491 |
| Data | 2013-05-10 |
| (30) | Numeris | Data | Šalis |
| 201161533082 P | 2011-09-09 | US |
| (72) |
WIEZOREK, Jeffrey, Scott, US
BACH, Bruce, Allen, US
|
| (73) |
Amgen Inc.,
One Amgen Center Drive, Thousand Oaks, California 91320-1799,
US
|
| (54) | USE OF HUMAN PAPILLOMAVIRUS STATUS IN ESTABLISHING USE OF AN AGENT THAT BINDS EGFR IN THE TREATMENT OF CANCER |
| USE OF HUMAN PAPILLOMAVIRUS STATUS IN ESTABLISHING USE OF AN AGENT THAT BINDS EGFR IN THE TREATMENT OF CANCER |